Autres langues Celltrion, Inc.

Actions

A068270

KR7068270008

Cours en clôture Korea S.E. Autres places de cotation 00:00:00 07/06/2024			Varia. 5j.	Varia. 1 janv.
191 100 ^KRW	+0,42 %		+8,46 %	-5,16 %

07/06	La mainmise d'AbbVie sur le marché de l'Humira suscite des inquiétudes quant aux biosimilaires	RE
24/05	Celltrion reçoit l'approbation de la Commission européenne pour Omlyclo® (CT-P39), le premier et le seul biosimilaire de l'omalizumab approuvé en Europe	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Celltrion's Avastin Biosimilar Gains 12% Market Share in Japan	07/06
AbbVie's tight grip on Humira market raises concerns about biosimilars	07/06
Tranche Update on Celltrion, Inc.'s Equity Buyback Plan announced on April 17, 2024.	04/06
Celltrion, Inc.'s Equity Buyback announced on April 17, 2024, has closed with 436,047 shares, representing 0.21% for KRW 80,550.32 million.	31/05
Celltrion Receives European Commission Approval of Omlyclo® (CT-P39), the First and Only Omalizumab Biosimilar Approved in Europe	24/05
Celltrion - Reality TV Star, Mollie Pearce, Backs Campaign to Tackle Inequalities in Condition That Impacts Millions of People Globally	20/05
Celltrion USA announces two-year data for ZYMFENTRA(infliximab-dyyb) to be presented at Digestive Disease Week (DDW) 2024 Conference	20/05
Court Cancels Injunction Hearings In Aflibercept BPCIA Litigation; Regeneron May Seek Temporary Restraining Orders	16/05
Celltrion's Q1 Attributable Profit Slumps 86%	10/05
MÄRKTE ASIEN/Tokio und Seoul sehr fest - Hongkong bleibt zurück	07/05
MÄRKTE ASIEN/Tokio und Seoul mit Nachholbedarf fest	07/05
Market Share of Celltrion’s Remsima Rises to 74% in Europe	24/04
MDL Panel Grants Transfer Of Aflibercept BPCIA Case	22/04
Celltrion, Inc. announces an Equity Buyback for 436,047 shares.	17/04
Celltrion, Inc. authorizes a Buyback Plan.	17/04
Tranche Update on Celltrion, Inc.'s Equity Buyback Plan announced on March 5, 2024.	28/03
Updates On Aflibercept BPCIA Litigation	26/03
Celltrion, Inc.'s Equity Buyback announced on March 5, 2024, has closed with 425,895 shares, representing 0.21% for KRW 78,072.21 million.	26/03
Fresenius Kabi's Actemra® Biosimilar Tyenne® (Tocilizumab-aazg) Approved In The U.S.	20/03
Celltrion, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	18/03

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Celltrion, Inc.

Actions

A068270

KR7068270008

Autres langues

Filtres